Abstract
Venous thromboembolism (VTE) is a major cause of maternal morbidity and mortality despite the possibility to prevent and treat the disorder. The hypercoagulability of normal pregnancy predispose to an approximately six-fold higher incidence of VTE in pregnancy. Identification of risk pregnancies and start of prophylaxis is essential, as is early diagnosis of VTE to prevent progression and pulmonary embolism. For anticoagulant treatment and prophylaxis in pregnancy, low molecular weight heparin is the drug of choice and prophylaxis, if indicated, should initiate as soon as pregnancy is confirmed.
MeSH terms
-
Anticoagulants / therapeutic use
-
Female
-
Heparin, Low-Molecular-Weight / therapeutic use
-
Humans
-
Incidence
-
Pregnancy
-
Pregnancy Complications, Cardiovascular* / diagnosis
-
Pregnancy Complications, Cardiovascular* / drug therapy
-
Pregnancy Complications, Cardiovascular* / epidemiology
-
Pregnancy Complications, Cardiovascular* / prevention & control
-
Risk Assessment
-
Risk Factors
-
Venous Thromboembolism* / diagnosis
-
Venous Thromboembolism* / drug therapy
-
Venous Thromboembolism* / epidemiology
-
Venous Thromboembolism* / prevention & control
Substances
-
Anticoagulants
-
Heparin, Low-Molecular-Weight